RARG

Across TCGA pan-cancer cohorts, RARG mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RARG data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RARG mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RARG expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, PDAC, and LSCC are the cancer types where RARG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.794	0.440	.011	12	view →
PDAC	OS	Median	II,III,IV	0.264	0.602	.048	6	view →
LSCC	OS	Tertile	All	0.669	0.946	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RARG–GBM (DFS)

Open the GBM breakdown →